Glow Blend (BPC-157 + TB-500 + GHK-Cu)

The GLOW Peptide Blend is a widely studied research blend that combines GHK-Cu, BPC-157, and TB-500 in one formula.

$250.00

9 in stock

GLOW Peptide Blend (GHK-Cu (50mg) + BPC-157 (10mg) + TB-500 (10mg)) 70mg

The GLOW Peptide Blend is a widely studied research blend that combines GHK-Cu (50mg), BPC-157 (10mg), and TB-500 (10mg) in one formula. Researchers are investigating their potential roles in tissue repair, cell migration, vascular support, and extracellular matrix signaling in the lab environment. This blend is intended for laboratory research use only. Note: The blend is not approved for human consumption by the FDA, and at Orion Peptides, we sell it only for research purposes and lab studies.

Composition of The Glow Blend

Product	Composition
GHK-Cu	50mg
TB-500	10mg
BPC-157	10mg

Characteristics of Component Peptides

1. GHK-Cu

GHK-Cu is a naturally occurring peptide that has been extensively researched for its health-supporting benefits over several decades. Pickart and Margo

2. BPC-157

lina (2018) showed that GHK-Cu modifies the expression of about 31.2% of human genes, many of which are involved in tissue repair, anti-inflammatory signaling, and redox regulation. When studied for its effects on collagen synthesis, GHK-Cu is a proven stimulator of collagen types I and III and elastin production. Researchers have consistently demonstrated collagen synthesis augmentation of both molecules in the pico- to nanomolar concentration range in various cell cultures and dermal models. In human dermal fibroblast cultures, décorin production was shown to increase by 302%. In macrophage cell cultures, GHK-Cu inhibited NF-B p65 and p38 MAPK signaling while attenuating the inflammatory markers TNF- and IL-6. BPC-157 is a 15-amino acid synthetic peptide derived from human gastric juice. Its primary research mechanism of action involves modulation of the nitric oxide signaling pathway. BPC-157 selectively upregulates VEGFR2 without an accompanying increase in VEGF-A, a precisely targeted angiogenic signal that has been demonstrated across numerous preclinical models. BPC-157 also activated the FAK-paxillin signaling pathway. This increased phosphorylation of focal adhesion kinase and paxillin proteins influences cell adhesion and migratory signaling pathways. A 2025 systematic review of 544 articles on BPC-157 demonstrated consistent tissue repair signaling throughout a wide variety of models, and measured reductions in TNF-, IL-6, IL-1, and COX-2 expression.

3. TB-500 – The Thymosin Beta-4 Synthetic Fragment

TB-500 is a synthetic 15-amino acid peptide corresponding to the active region of the 43-amino acid peptide Thymosin Beta-4 (T-beta-4). As a protein that strongly binds monomeric G-actin in a 1:1 ratio, it directly affects cytoskeletal reorganization, a fundamental process in cell motility, differentiation, and tissue remodeling. Rat models of wound healing treated with TB-500 showed 42-61% greater re-epithelialization with improved collagen formation compared to controls. TB-500 was also shown to affect tissue remodeling in its anti-fibrotic pathway. In rats with liver injury, it caused organization of mature collagen fiber formation and dramatically reduced myofibroblast creation. It also appears to exhibit bi-directional effects on inflammation through significant reduction of TNF-, IL-6, and substantial increases of IL-10 in preclinical rat models (a 6.2-fold reduction of TNF-, 4.1-fold of IL-6, and 8.1-fold of IL-10), indicating it can reduce pro-inflammatory signals while bolstering anti-inflammatory response.

Rationale for a Multi- Pathway Approach

The GHK-Cu peptide acts via gene modulation to affect the extracellular matrix, inflammation, and antioxidant balance. BPC-157 affects the VEGFR2 pathway to promote angiogenesis and cell migration. TB-500 supports actin reorganization and also affects cell migration and fibrosis while modulating inflammation through cytokine balance. When acting together, these three peptides may complement each other across many relevant research pathways for tissue repair models, influencing inflammation, vasculature, cell movement, and matrix remodeling sequentially. It is hypothesized that this multi-target strategy offers a more holistic research approach than single-peptide studies in some models.

Research-Based Benefits

The following research-based findings are provided solely for the benefit of scientific and academic consideration and have not been evaluated by the U.S. Food and Drug Administration.

1. Collagen Synthesis and Extracellular Matrix Remodeling

GHK-Cu’s well-documented stimulation of collagen types I and III, as well as elastin and decorin at nanomolar concentrations in all known models, forms a critical pillar in research into extracellular matrix formation. Combined with the documented increase of collagen and reticulin and significant growth of blood vessels in models using BPC-157, this dual-action matrix remodeling model shows promise for comprehensive research.

2. Angiogenesis and Vascular Support

Both BPC-157 and TB-500 work together to help vascular growth. BPC-157 actively upregulates the VEGFR2 pathway while TB-500 enhances endothelial cell migration. In research models, the ability of the GLOW Blend to promote angiogenesis and tissue repair signaling on multiple levels could be highly beneficial, addressing ischemia and wound healing.

3. Multi-Pathway Anti-Inflammatory Modulation

This peptide blend exhibits three unique molecular mechanisms working synergistically to fight inflammation. GHK-Cu targets the NF-κB and p38 MAPK signaling pathways. BPC-157 reduces inflammation at the signaling level of inflammatory markers such as TNF-, IL-6, and COX-2. TB-500 may show bi-phasic effects on inflammation, reducing some pro-inflammatory factors while upregulating IL-10, a key anti-inflammatory cytokine.

4. Migration of cells and regeneration of tissues.

Both BPC-157 and TB-500 enhance cell movement and tissue reorganization in models of wound healing and tissue repair. TB-500 binds G-actin, which promotes directed cell motility and tissue remodeling in rat wound models, with significantly improved re-epithelialization and collagen deposition, and decreased myofibroblast production. BPC-157, on the other hand, activated the FAK-paxillin pathway, which helps to recruit fibroblasts.

5. Antioxidant Properties

GHK-Cu directly impacts antioxidant systems within the cells by regulating the activity of antioxidant enzymes, such as matrix metalloproteinases. This property provides an additional function to the GLOW Blend, away from the key action of BPC-157 and TB-500, as far as antioxidant research is concerned.

6. Neuroprotective Effects

In preclinical models, both TB-500 and BPC-157 have shown evidence of neuroprotection. TB-500 improved function after traumatic brain injury even when administered 24 hours after injury. In addition, preclinical studies show that BPC-157 interacts with dopaminergic and nitric oxide signaling pathways in animal models. These promising early results may indicate the GLOW Blend is a compound to follow closely in future neurological research.

Analytical Specifications

Purity: 99% (Verified via HPLC and mass spectrometry)
Form: Lyophilized powder
Storage: Long-term storage at 20°C; 2-8°C after reconstitution
Reconstitution: Mix immediately before use with sterile bacteriostatic water
Stability: Do not repeatedly freeze-thaw.

Disclaimer

The GLOW Peptide Blend sold by Orion Peptide.org is strictly for research purposes only. This product should not be ingested, self-administered, or used for any therapeutic purpose. The U.S. Food and Drug Administration has not evaluated this product. BPC-157 and TB-500 are prohibited by the WADA Prohibited List. Research must be carried out by individuals with appropriate training and in accordance with institutional and regulatory guidelines. These statements have not been evaluated by the U.S. Food and Drug Administration.

References

Research Use Only

This product is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Chemical Properties

Chemical Formula	BPC-157: C62H98N16O22 TB-500: C212H350N56O78S GHK-Cu: C28H48CuN12O8
Molecular Mass	BPC-157: 1419.5 g/mol TB-500: 4963 g/mol GHK-Cu: 744.3 g/mol
Monoisotopic Mass	BPC-157: 1418.70415882 Da TB-500: 4960.4863169 Da GHK-Cu: 743.301404 Da
Polar Area	BPC-157: 573 Å² TB-500: 2250 Å² GHK-Cu: 352 Å²
Complexity	BPC-157: 3040 TB-500: 12200 GHK-Cu: 952
XLogP	BPC-157: -9 TB-500: -43.5 GHK-Cu: N/A
Heavy Atom Count	BPC-157: 100 TB-500: 347 GHK-Cu: 49
Hydrogen Bond Donor Count	BPC-157: 16 TB-500: 72 GHK-Cu: 12
Hydrogen Bond Acceptor Count	BPC-157: 24 TB-500: 88 GHK-Cu: 14
Rotatable Bond Count	BPC-157: 39 TB-500: 180 GHK-Cu: 22
CID	BPC-157: 9941957 TB-500: 16132341 GHK-Cu: 133697840
InChI	BPC-157: InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1 TB-500: InChI=1S/C212H350N56O78S/c1-16-106(7)166(261-190(323)131(64-75-160(292)293)231-172(305)109(10)228-174(307)134(78-91-347-15)245-196(329)140(98-165(302)303)255-201(334)147-53-39-88-266(147)209(342)135(52-29-38-87-221)250-197(330)139(97-164(300)301)254-198(331)143(100-269)229-113(14)276)204(337)246-129(62-73-158(288)289)187(320)233-118(47-24-33-82-216)179(312)252-137(94-114-42-19-18-20-43-114)194(327)253-138(96-163(298)299)195(328)237-121(50-27-36-85-219)181(314)258-144(101-270)199(332)239-119(48-25-34-83-217)178(311)251-136(92-104(3)4)193(326)236-116(45-22-31-80-214)175(308)235-122(51-28-37-86-220)189(322)263-168(110(11)273)207(340)249-133(66-77-162(296)297)192(325)264-169(111(12)274)206(339)248-126(58-69-152(224)279)184(317)243-128(61-72-157(286)287)186(319)234-120(49-26-35-84-218)180(313)256-142(95-153(225)280)211(344)268-90-40-54-148(268)202(335)257-141(93-105(5)6)210(343)267-89-41-55-149(267)203(336)259-145(102-271)200(333)238-117(46-23-32-81-215)177(310)244-132(65-76-161(294)295)191(324)265-170(112(13)275)208(341)262-167(107(8)17-2)205(338)247-130(63-74-159(290)291)188(321)241-125(57-68-151(223)278)183(316)242-127(60-71-156(284)285)185(318)232-115(44-21-30-79-213)176(309)240-124(56-67-150(222)277)173(306)227-108(9)171(304)226-99-154(281)230-123(59-70-155(282)283)182(315)260-146(103-272)212(345)346/h18-20,42-43,104-112,115-149,166-170,269-275H,16-17,21-41,44-103,213-221H2,1-15H3,(H2,222,277)(H2,223,278)(H2,224,279)(H2,225,280)(H,226,304)(H,227,306)(H,228,307)(H,229,276)(H,230,281)(H,231,305)(H,232,318)(H,233,320)(H,234,319)(H,235,308)(H,236,326)(H,237,328)(H,238,333)(H,239,332)(H,240,309)(H,241,321)(H,242,316)(H,243,317)(H,244,310)(H,245,329)(H,246,337)(H,247,338)(H,248,339)(H,249,340)(H,250,330)(H,251,311)(H,252,312)(H,253,327)(H,254,331)(H,255,334)(H,256,313)(H,257,335)(H,258,314)(H,259,336)(H,260,315)(H,261,323)(H,262,341)(H,263,322)(H,264,325)(H,265,324)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,296,297)(H,298,299)(H,300,301)(H,302,303)(H,345,346)/t106-,107-,108-,109-,110+,111+,112+,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,166-,167-,168-,169-,170-/m0/s1 GHK-Cu: InChI=1S/2C14H24N6O4.Cu/c215-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h27-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24);/t2*10-,11-;/m00./s1
InChIKey	BPC-157: HEEWEZGQMLZMFE-RKGINYAYSA-N TB-500: UGPMCIBIHRSCBV-XNBOLLIBSA-N GHK-Cu: RIPDSRHLQNAZOH-XTQNZXNBSA-N
IUPAC Name	BPC-157: (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid TB-500: (4S)-4-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-3-phenylpropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-4-amino-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]acetyl]amino]-5-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-5-oxopentanoic acid GHK-Cu: bis((2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid);copper
SMILES	BPC-157: C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN TB-500: CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C GHK-Cu: C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN.C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN.[Cu]

Certificate of Analysis

Quality

Every batch of Glow Blend (BPC-157 + TB-500 + GHK-Cu) is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥98%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All products undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all products. Contact us with your order number to request batch-specific documentation.

COA Lab Tests

Each product batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the product meets strict research-grade standards.

Storage & Handling

Storage Guidelines

Like all other research peptides, Glow peptide is also sensitive to heat, light and improper handling. To maintain its stability and structural integrity throughout its use, it is important to understand the correct storage guidelines.

After Reconstitution (Liquid Form)

Once the bottle is opened it is important to refrigerate it immediately at 2°C to 8°C (36°F to 46°F after each use.
Avoid freezing, because with freezing, there is a risk that the peptide structure might get damaged due to ice crystal formation.
Avoid shaking the vial, and gently swirl if mixing is required.

Before Use (Unopened Vial)

It is important to store the unopened vial in a refrigerator at 2°C to 8°C (36°F to 46°F)
Maintaining a stable temperature is really important, and avoiding too many fluctuations.
It is best to keep it in the main refrigerator compartment instead of placing it at the door.
To protect the material from light exposure, it is important to keep the vial in its original packaging.

After Reconstitution (Liquid Form)

Once the bottle is opened it is important to refrigerate it immediately at 2°C to 8°C (36°F to 46°F after each use.
Avoid freezing, because with freezing, there is a risk that the peptide structure might get damaged due to ice crystal formation.
Avoid shaking the vial, and gently swirl if mixing is required.

Glow Blend (BPC-157 + TB-500 + GHK-Cu)

Bulk Pricing – Save More

GLOW Peptide Blend (GHK-Cu (50mg) + BPC-157 (10mg) + TB-500 (10mg)) 70mg

Composition of The Glow Blend

Characteristics of Component Peptides

1. GHK-Cu

2. BPC-157

3. TB-500 – The Thymosin Beta-4 Synthetic Fragment

Rationale for a Multi- Pathway Approach

Research-Based Benefits

1. Collagen Synthesis and Extracellular Matrix Remodeling

2. Angiogenesis and Vascular Support

3. Multi-Pathway Anti-Inflammatory Modulation

4. Migration of cells and regeneration of tissues.

5. Antioxidant Properties

6. Neuroprotective Effects

Analytical Specifications

Disclaimer

References

Research Use Only

Chemical Properties

Certificate of Analysis

Quality

HPLC Analysis

Mass Spectrometry (MS)

Third-Party Testing

Request COA

COA Lab Tests

Storage & Handling

Storage Guidelines

After Reconstitution (Liquid Form)

Before Use (Unopened Vial)

After Reconstitution (Liquid Form)

Related Products

Purity

Storage

5 Amino 1MQ – 10mg

AOD-9604 – 10mg

AOD-9604 – 2mg

AOD-9604 – 5mg

AOD-9604 (10mg) + Tesamorelin (10mg) Research Kit

Bacteriostatic Water 10ml

Bacteriostatic Water 3ml

BPC 157 (10mg) + TB 500 (10mg) Blend

BPC 157 (5mg) +TB 500 (5mg) Blend

BPC-157 – 10mg

BPC-157 – 5mg

BPC-157 (10 mg) + TB-500 (20 mg) Blend

BPC-157 (10mg) + TB-500 (10mg) Bundle

BPC-157 (5mg) + TB-500 (5mg) Starter Kit + BAC Water (10ml) | Peptide Research Bundle

CJC-1295 (No DAC) – 2mg

CJC-1295 (No DAC) – 5mg

CJC-1295 (No DAC) (5mg) + Ipamorelin (5mg) Research Bundle

CJC-1295 No DAC (10mg) + Ipamorelin (10mg) Blend

CJC-1295 NO DAC (5mg) + Ipamorelin (5mg) Blend

DSIP – 10mg

DSIP – 5mg

Epithalon (20mg) + SS-31 (Elamipretide) (5mg) Longevity Research Kit

Epithalon (Epitalon) – 10mg

Epithalon (Epitalon) – 20mg

GHK-Cu – 100mg

GHK-Cu – 10mg

GHK-Cu – 50mg

GHK-Cu (50mg) + Epithalon (10mg) Bundle

Glow Blend (BPC-157 + TB-500 + GHK-Cu)

Glutathione (10ML) – 500mg

Glutathione (10ML) – 600mg

IGF-1 LR3 – 1mg

Ipamorelin – 10mg

Ipamorelin – 2mg